369 related articles for article (PubMed ID: 17285366)
21. Management of cystic prolactinomas: a review.
Nakhleh A; Shehadeh N; Hochberg I; Zloczower M; Zolotov S; Taher R; Daoud Naccache D
Pituitary; 2018 Aug; 21(4):425-430. PubMed ID: 29654440
[TBL] [Abstract][Full Text] [Related]
22. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
23. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
24. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
[No Abstract] [Full Text] [Related]
25. The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
Recouvreux MV; Camilletti MA; Rifkin DB; Díaz-Torga G
J Endocrinol; 2016 Mar; 228(3):R73-83. PubMed ID: 26698564
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of a giant prolactinoma.
Fernandes V; Santos MJ; Almeida R; Marques O
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26590188
[TBL] [Abstract][Full Text] [Related]
28. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
31. Management of resistant prolactinomas.
Olafsdottir A; Schlechte J
Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
[TBL] [Abstract][Full Text] [Related]
32. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
33. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
34. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
35. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
37. Management of psychosis associated with a prolactinoma: case report and review of the literature.
Ali S; Miller KK; Freudenreich O
Psychosomatics; 2010; 51(5):370-6. PubMed ID: 20833935
[TBL] [Abstract][Full Text] [Related]
38. Medical treatment of prolactinomas.
Molitch ME
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
[TBL] [Abstract][Full Text] [Related]
39. [Dopamine-agonist resistant prolactinomas: diagnosis and management].
Musolino NR; Passos VQ
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):641-50. PubMed ID: 16444347
[TBL] [Abstract][Full Text] [Related]
40. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]